Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 avr. 2025 16h05 HE | Source: Tvardi Therapeutics

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi shares to begin...
19 mars 2025 08h00 HE | Source: Tvardi Therapeutics

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research

Tvardi’s previously announced merger with publicly traded Cara Therapeutics is on-track to close in 1H 2025 TTI-101 is currently being evaluated in a Phase 2 study in patients with idiopathic...
19 févr. 2025 08h30 HE | Source: Tvardi Therapeutics

Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

HOUSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies...